title: Cancer nanomedicines: oversold or underappreciated?
authors.affiliation: a Department of Clinical Chemistry and Haematology , University Medical Center Utrecht , Utrecht , The Netherlands.|b Department of Biochemistry and Molecular Biology , University of British Columbia , Vancouver , British Columbia , Canada.
authors.forename: Roy
authors.initials: R
authors.lastname: van der Meel
authors.affiliation: c Department of Nanomedicine and Theranostics, Institute for Experimental Molecular Imaging , RWTH Aachen University Clinic , Aachen , Germany.|d Department of Targeted Therapeutics, MIRA Institute for Biomedical Technology and Technical Medicine , University of Twente , Enschede , The Netherlands.|e Department of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences , Utrecht University , Utrecht , The Netherlands.
authors.forename: Twan
authors.initials: T
authors.lastname: Lammers
authors.affiliation: e Department of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences , Utrecht University , Utrecht , The Netherlands.
authors.forename: Wim E
authors.initials: WE
authors.lastname: Hennink
keywords: Cancer nanomedicines; Clinical translation; Clinical trials; Combination treatment; Drug delivery; Drug targeting; EPR effect; Triggered release